Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Suzannah Chapman"'
Autor:
Jonathan Lind Martinsson, Peter Arlett, Rick A. Vreman, Martin Wenzl, Inneke van de Vijver, Roisin Adams, Anna Nachtnebel, Lonneke Timmers, Hans-Georg Eichler, Einar Andreassen, Suzannah Chapman, Elias Pean, Tove Ragna Reksten, Guido Rasi, Wim G. Goettsch, Marc Van de Casteele, Jordi Llinares-Garcia
Publikováno v:
International Journal of Technology Assessment in Health Care, 37(1), 1. Cambridge University Press
Performance-based managed entry agreements (PB-MEAs) might allow patient access to new medicines, but practical hurdles make competent authorities for pricing and reimbursement (CAPR) reluctant to implement PB-MEAs. We explored if the feasibility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4f7d48d3f7dd1a95acfc3ddd658259
https://lirias.kuleuven.be/handle/123456789/679492
https://lirias.kuleuven.be/handle/123456789/679492
Publikováno v:
OECD Health Working Papers.
With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide – and sustain – access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f57228f145a7a1cdc082efe55859aafe
https://doi.org/10.1787/4b2e9cb9-en
https://doi.org/10.1787/4b2e9cb9-en
Autor:
Martin Wenzl, Suzannah Chapman
Publikováno v:
OECD Health Working Papers.
This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::734e74d6654c9a8936d2cb0a5b651d54
https://doi.org/10.1787/6e5e4c0f-en
https://doi.org/10.1787/6e5e4c0f-en
Autor:
Samantha A. Hollingworth, Daniel McKavanagh, Matthew Burge, Euan Walpole, Ian McPherson, Suzannah Chapman
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 13:e253-e261
Metastatic colorectal cancer has a large burden of disease in Australia. Medical therapy is fundamental to extending survival and improving quality of life. The benefits of two costly medicines, bevacizumab and cetuximab, used in Australia remain unc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c9fc88735a796d7f1906217a2e8db46
https://doi.org/10.1111/ajco.12518
https://doi.org/10.1111/ajco.12518